Evidence map›Paper›PMID 39192219›Full record

ArticleBMC complementary medicine and therapies2024

Potential mechanism prediction of indole-3-propionic acid against diminished ovarian reserve via network pharmacology, molecular docking and experimental verification.

Ahui Liu, Zhijun Liu, Haofei Shen, Wenjing Du, Yanbiao Jiang, Liyan Wang, Rui Zhang, Panpan Jin, Xuehong Zhang

Abstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ahui Liu *The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
Zhijun Liu *The Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Haofei Shen *The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
Wenjing DuThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
Yanbiao JiangThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
Liyan WangReproductive Medicine Center, The First Hospital of Lanzhou University, Chengguan District, No. 1 Dong Gang Xi Road, Lanzhou, Gansu, 730000, China.
Rui ZhangReproductive Medicine Center, The First Hospital of Lanzhou University, Chengguan District, No. 1 Dong Gang Xi Road, Lanzhou, Gansu, 730000, China.
Panpan JinReproductive Medicine Center, The First Hospital of Lanzhou University, Chengguan District, No. 1 Dong Gang Xi Road, Lanzhou, Gansu, 730000, China. 331999640@qq.com.
Xuehong ZhangReproductive Medicine Center, The First Hospital of Lanzhou University, Chengguan District, No. 1 Dong Gang Xi Road, Lanzhou, Gansu, 730000, China. zhangxueh@lzu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOxidative stress (OS) is one of the major causes of ovarian aging and dysfunction. Indole-3-propionic acid (IPA) is an indole compound derived from tryptophan with free radical scavenging and antioxidant properties, and thus may have potential applications in protecting ovarian function, although the exact mechanisms are unknown. This study aims to preliminarily elucidate the potential mechanisms of IPA that benefit ovarian reserve function through network pharmacology, molecular docking, and experimental verification.

methodsThe related protein targets of IPA were searched on SwissTargetPrediction, TargetNet, BATMAN-TCM, and PharmMapper databases. The potential targets of diminished ovarian reserve (DOR) were identified from OMIM, GeneCards, DrugBank, and DisGeNET databases. The common targets were uploaded directly to the STRING database to construct PPI networks. We then performed GO and KEGG enrichment analysis on the targets. Subsequently, molecular docking and molecular dynamics simulation were used to validate the binding conformation of IPA to candidate targets. Furthermore, we carried out in vitro experiments to validate the prediction results of network pharmacology.

resultsWe identified a total of 61 potential targets for the interaction of IPA with DOR. The PPI network topological parameter analysis yielded 13 hub genes for DOR treatment. The GO biological process enrichment analysis identified 293 entries, mainly enriched in aging, signal transduction, response to hypoxia, negative regulation of apoptotic process, and positive regulation of cell proliferation. The KEGG enrichment analysis mainly included lipid and atherosclerosis, progesterone-mediated oocyte maturation, AGE-RAGE, relaxin, estrogen, and other signaling pathways. The molecular docking further revealed the direct binding of IPA with six hub proteins including NOS3, AKT1, EGFR, PPARA, SRC, and TNF. In vitro experiments showed that IPA pretreatment attenuated H

conclusionWe systematically illustrated the potential protective effects of IPA against DOR through multiple targets and pathways using network pharmacology, and further verified the cytoprotective effect and antioxidant properties of IPA through in vitro experiments. These findings provide new insights into the targets and molecular mechanisms whereby IPA improves DOR.

Indexed as

IndolesMolecular Docking SimulationNetwork PharmacologyAntioxidantsFemaleHumansOvarian ReserveOxidative StressAntioxidantsindolepropionic acidIndolesDiminished ovarian reserveExperimental verificationIndole-3-propionic acidMolecular dockingMolecular dynamics simulationNetwork pharmacology

Identifiers

PMID39192219
PMCPMC11348684

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.